Reported: CMS’s November 4, 2026 final rule expands Medicare’s DME benefit for certain external infusion pumps and associated home infusion drugs, effective April 1, 2027. Conditions include FDA labeling requiring professional administration or supervision, a qualified home infusion therapy supplier, and labeling specifying at least 12 infusions yearly—not necessarily once each month.
DomAfina’s take: coverage is not automatic, and home health enrollment alone is not proof of qualified infusion-supplier status. Review your referral pathway with the prescribing clinician, infusion supplier and billing team. Confirm the drug and pump meet requirements, who provides supervision, and who handles supplies and follow-up. Put those responsibilities in the handoff before promising patients a covered service.
Source reviewed: CMS final-rule fact sheet, November 4, 2026. The source supports the reported update; the operational recommendations are DomAfina’s analysis.


Discussion
Comments and replies
Keep it useful and on this article’s subject. No profanity, hate, threats, harassment, spam, advertising, solicitation, personal or patient information. Off-topic comments are held for moderation and automatically deleted after 10 days if not approved.
Loading recent comments…